ECSP066735A - Formas polimórficas de un agonista de gabaa - Google Patents

Formas polimórficas de un agonista de gabaa

Info

Publication number
ECSP066735A
ECSP066735A EC2006006735A ECSP066735A ECSP066735A EC SP066735 A ECSP066735 A EC SP066735A EC 2006006735 A EC2006006735 A EC 2006006735A EC SP066735 A ECSP066735 A EC SP066735A EC SP066735 A ECSP066735 A EC SP066735A
Authority
EC
Ecuador
Prior art keywords
polymodic
forms
gabaa agonist
gabaa
agonist
Prior art date
Application number
EC2006006735A
Other languages
English (en)
Inventor
Vincent Brett Cooper
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31971783&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066735(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of ECSP066735A publication Critical patent/ECSP066735A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se revelan dos nuevos monohidratos cristalinos y dos nuevos anhidratos cristalinos de gaboxadol junto con los procedimientos para prepararlos
EC2006006735A 2004-01-30 2006-07-28 Formas polimórficas de un agonista de gabaa ECSP066735A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0402118.4A GB0402118D0 (en) 2004-01-30 2004-01-30 Polymorphic forms of a GABAA agonist

Publications (1)

Publication Number Publication Date
ECSP066735A true ECSP066735A (es) 2006-10-31

Family

ID=31971783

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006735A ECSP066735A (es) 2004-01-30 2006-07-28 Formas polimórficas de un agonista de gabaa

Country Status (34)

Country Link
US (2) US7262300B2 (es)
EP (2) EP2042505A1 (es)
JP (1) JP4917440B2 (es)
KR (1) KR101210361B1 (es)
CN (1) CN1914212B (es)
AR (1) AR047511A1 (es)
AT (1) ATE414088T1 (es)
AU (1) AU2005209473B2 (es)
BR (1) BRPI0506858A (es)
CA (1) CA2554536C (es)
CO (1) CO5700743A2 (es)
CY (1) CY1108647T1 (es)
DE (1) DE602005010975D1 (es)
DK (1) DK1713813T3 (es)
DO (1) DOP2005000013A (es)
EA (1) EA009413B1 (es)
EC (1) ECSP066735A (es)
ES (1) ES2314613T3 (es)
GB (2) GB0402118D0 (es)
HR (1) HRP20080614T3 (es)
IL (1) IL176863A0 (es)
MA (1) MA28364A1 (es)
MX (1) MXPA06008595A (es)
MY (1) MY139525A (es)
NO (1) NO20063843L (es)
NZ (1) NZ548191A (es)
PE (1) PE20050769A1 (es)
PL (1) PL1713813T3 (es)
PT (1) PT1713813E (es)
SI (1) SI1713813T1 (es)
TW (1) TWI345972B (es)
UA (1) UA87487C2 (es)
WO (1) WO2005073237A2 (es)
ZA (1) ZA200605307B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
US9072662B2 (en) 2004-03-29 2015-07-07 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US20060063802A1 (en) 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
DE102005004343A1 (de) * 2005-01-25 2006-08-10 Eberhard-Karls-Universität Tübingen Universitätsklinikum Behandlung von Phantomphänomenen
EP1848420A4 (en) * 2005-01-28 2008-01-23 Merck & Co Inc POLYMORPH SHAPES OF A GABAA AGONIST
PT1928405E (pt) 2005-09-28 2014-10-20 Auris Medical Ag Composições farmacêuticas para o tratamento de distúrbios do ouvido interno
CN102093387B (zh) * 2009-12-10 2012-07-25 天津泰普医药知识产权流转储备中心有限公司 4,5,6,7-四氢异噁唑并[5,4-c]吡啶-3-醇一水合物的晶型化合物
WO2013087090A1 (en) 2011-12-12 2013-06-20 Auris Medical Ag Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system
KR20240160666A (ko) 2015-07-17 2024-11-11 오비드 테라퓨틱스 인크. 가복사돌로 발달장애들을 치료하는 방법들
EP4233861A3 (en) * 2016-08-11 2023-10-11 Ovid Therapeutics, Inc. Compositions for treatment of essential tremor
JP2019535760A (ja) * 2016-11-22 2019-12-12 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． フルピルチンを用いた発達障害および／または発作性障害の処置方法
US10071083B2 (en) * 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US10813918B2 (en) 2017-08-04 2020-10-27 Ovid Therapeutics Inc. Use of Gaboxadol in the treatment of diabetes and related conditions
AU2019345312A1 (en) 2018-09-20 2021-03-25 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
WO2020106927A1 (en) 2018-11-21 2020-05-28 Certego Therapeutics Gaboxadol for reducing risk of suicide and rapid relief of depression
CN113423399A (zh) 2018-12-17 2021-09-21 奥维德医疗公司 加波沙朵用于治疗非24小时睡眠-觉醒障碍的用途
WO2021127308A1 (en) 2019-12-18 2021-06-24 Ovid Therapeutics Inc. GABOXADOL FOR THERAPEUTIC TREATMENT OF 1p36 DELETION SYNDROME
MX2022014599A (es) 2020-05-20 2022-12-16 Certego Therapeutics Inc Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270278A (da) * 1977-06-20 1978-12-21 Krogsgaard Larsen P Cycliske aminosyrer
US4315934A (en) * 1979-09-24 1982-02-16 Sandoz Ltd. Organic compounds
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4352731A (en) * 1980-11-03 1982-10-05 Occidental Research Corporation Apparatus for selective wetting of particles
DE19525598C2 (de) * 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
UA52661C2 (uk) * 1996-06-14 2003-01-15 Ново Нордіск А/С Безводна кристалічна форма гідрохлориду r(-)-n-(4,4-ди(3-метилтієн-2-іл)бут-3-еніл) ніпекотинової кислоти
AU7405000A (en) 1999-09-28 2001-04-30 H. Lundbeck A/S Melt granulated composition and modified release dosage form prepared from said composition
AR031473A1 (es) 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
WO2002094255A1 (de) 2001-05-18 2002-11-28 Lonza Ag Verfahren zur herstellung fester formulierungen von natrium-3-hydroxy-3-methylbutyrat
EP1389091A1 (en) 2001-05-21 2004-02-18 H. Lundbeck A/S Granular preparations of gaboxadol
CN100491366C (zh) * 2002-09-03 2009-05-27 华晶基因技术有限公司 汉黄芩素用作治疗焦虑症的药物的用途
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
EP1641456B1 (en) * 2003-06-25 2010-03-03 H. Lundbeck A/S Gaboxadol for treating depression and other affective disorders
AR045540A1 (es) 2003-09-05 2005-11-02 Lundbeck & Co As H Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip)
EP1663218A1 (en) 2003-09-10 2006-06-07 MERCK SHARP & DOHME LTD. Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
TW200528098A (en) 2003-12-18 2005-09-01 Lundbeck & Co As H Treatment of insomnia in human patients
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
AU2004324938A1 (en) 2004-06-29 2006-05-26 H. Lundbeck A/S Treatment of neuropathic pain, fibromyalgia or rheumatoid arthritis
GB0417558D0 (en) 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
EP1848420A4 (en) 2005-01-28 2008-01-23 Merck & Co Inc POLYMORPH SHAPES OF A GABAA AGONIST
EP1863808A1 (en) 2005-03-18 2007-12-12 Transform Pharmaceuticals, Inc. Gaboxadol forms, compositions thereof, and related methods
EP1906953A4 (en) 2005-04-29 2009-05-20 Lundbeck & Co As H ACID AND BASE SALT FORMS OF GABOXADOL

Also Published As

Publication number Publication date
AR047511A1 (es) 2006-01-25
AU2005209473A1 (en) 2005-08-11
MA28364A1 (fr) 2006-12-01
PE20050769A1 (es) 2005-10-04
PL1713813T3 (pl) 2009-04-30
TWI345972B (en) 2011-08-01
SI1713813T1 (sl) 2009-02-28
CA2554536C (en) 2012-09-18
KR20070007070A (ko) 2007-01-12
US7262300B2 (en) 2007-08-28
NZ548191A (en) 2010-04-30
EA009413B1 (ru) 2007-12-28
US20050171142A1 (en) 2005-08-04
DOP2005000013A (es) 2005-08-15
DE602005010975D1 (de) 2008-12-24
CN1914212A (zh) 2007-02-14
JP2007519697A (ja) 2007-07-19
JP4917440B2 (ja) 2012-04-18
CO5700743A2 (es) 2006-11-30
UA87487C2 (ru) 2009-07-27
WO2005073237A2 (en) 2005-08-11
US8236958B2 (en) 2012-08-07
CA2554536A1 (en) 2005-08-11
WO2005073237A3 (en) 2005-10-20
MXPA06008595A (es) 2006-08-28
ES2314613T3 (es) 2009-03-16
ATE414088T1 (de) 2008-11-15
EP2042505A1 (en) 2009-04-01
GB0501847D0 (en) 2005-03-09
NO20063843L (no) 2006-08-29
EA200601404A1 (ru) 2006-12-29
TW200534856A (en) 2005-11-01
BRPI0506858A (pt) 2007-05-29
DK1713813T3 (da) 2009-02-16
HK1096547A1 (en) 2007-06-01
ZA200605307B (en) 2007-11-28
GB0402118D0 (en) 2004-03-03
EP1713813B1 (en) 2008-11-12
KR101210361B1 (ko) 2012-12-10
EP1713813A2 (en) 2006-10-25
PT1713813E (pt) 2008-12-26
US20070259912A1 (en) 2007-11-08
IL176863A0 (en) 2006-10-31
MY139525A (en) 2009-10-30
CY1108647T1 (el) 2014-04-09
HRP20080614T3 (en) 2009-01-31
CN1914212B (zh) 2010-10-06
AU2005209473B2 (en) 2010-03-04
GB2410434A (en) 2005-08-03

Similar Documents

Publication Publication Date Title
DOP2005000013A (es) Formas polimórficas de 4,5,6,7-tetrahidroisoxazolo[5,4-c]piridin-3-ol
ES2458216T8 (es) Nuevos ARNip y métodos de uso de los mismos
CR10743A (es) Derivados de azaadamantano y metodos de uso de los mismos
CR10372A (es) Anticuerpos anti-tat226 e inmunoconjugados
BRPI0720993A2 (pt) métodos de uso para análogos de ciclopamina
ES2884326T8 (es) Kit de tornillo de expansión y método para su uso
BRPI0811635A2 (pt) Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos
SV2011003832A (es) Derivados de ciclohexil-amida y su uso como antagonistas de los receptores de crf-1
BRPI0818003A2 (pt) inibidores de csf-1r, composições e métodos de uso
AR063532A1 (es) Anticuerpos e inmunoconjugados y sus usos
CR20140180A (es) Inhibidores macrocíclicos de serina proteasas de hepatitis c
MX386852B (es) Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus metodos de uso.
DK1888582T3 (da) Imidazo- og triazolopyridiner som hæmmere af 11-beta-hydroxysteroid dehydrigenase
DK1756679T3 (da) Fremgangsmåde til tidsstyring af et objekt
AR057237A1 (es) Metodos y composiciones para actuar sobre la poliubiquitina
BRPI0815659A2 (pt) Derivados de n-(arilamino) sulfonamidas incluindo polimorfos como inibidores de mek bem como composições, métodos de uso e métodos para preparar os mesmos
DK2094676T3 (da) Ny fremgangsmåde til fremstillingen af 2-iminothiazolidin-4-on-derivater
CL2009001686A1 (es) Procedimiento de preparacion de agomelatina; y los compuestos intermediarios considerados.
ES2530578T3 (es) Cristales y cristales reticulados de Proteína A y métodos de uso de los mismos
CL2008003095A1 (es) Procedeimiento de preparacion de dihidrotienopirimidas; uno de los compuestos intermediarios considerados; y el procedimiento de preparacion de dicho compuesto intermediario.
DK3805671T3 (da) Absorption af brændbart kølemiddel
ES1065291Y (es) Dispositivo para la mejora del rendimiento de los paneles solares
DK2167124T3 (da) Anvendelse af monomycolylglycerol (MMG) som adjuvans
UY30801A1 (es) Compuestos calciliticos
UY29434A1 (es) Derivados de tetrahidronaftalina, procedimientos para su preparación y su uso como inhibidores de la inflamacinn